GOVX Earnings — GeoVax Labs, Inc. New Post-ER Performance | BigEarnings
GOVX — GeoVax Labs, Inc. New
XNAS · Healthcare · Biotechnology
Price$2.06
Market Cap$10.7M
P/E—
52W Range$0.96 – $34.75
Next Earnings2026-07-27
About GeoVax Labs, Inc. New
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.
